nodes	percent_of_prediction	percent_of_DWPC	metapath
Bupivacaine—CYP1A2—chronic obstructive pulmonary disease	0.414	1	CbGaD
Bupivacaine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.05	0.13	CbGbCtD
Bupivacaine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.05	0.13	CbGbCtD
Bupivacaine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0392	0.102	CbGbCtD
Bupivacaine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.038	0.0992	CbGbCtD
Bupivacaine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.038	0.0992	CbGbCtD
Bupivacaine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0339	0.0884	CbGbCtD
Bupivacaine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0319	0.0832	CbGbCtD
Bupivacaine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0216	0.0562	CbGbCtD
Bupivacaine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.021	0.0548	CbGbCtD
Bupivacaine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0206	0.0536	CbGbCtD
Bupivacaine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0183	0.0478	CbGbCtD
Bupivacaine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0108	0.028	CbGbCtD
Bupivacaine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0102	0.0265	CbGbCtD
Bupivacaine—Levobupivacaine—CYP1A2—chronic obstructive pulmonary disease	0.000992	0.255	CrCbGaD
Bupivacaine—Lidocaine—EGFR—chronic obstructive pulmonary disease	0.000842	0.217	CrCbGaD
Bupivacaine—Ropivacaine—CYP1A2—chronic obstructive pulmonary disease	0.000639	0.165	CrCbGaD
Bupivacaine—Tocainide—CYP1A2—chronic obstructive pulmonary disease	0.000601	0.155	CrCbGaD
Bupivacaine—Lidocaine—CYP1A2—chronic obstructive pulmonary disease	0.000464	0.12	CrCbGaD
Bupivacaine—Tocainide—ALB—chronic obstructive pulmonary disease	0.000347	0.0893	CrCbGaD
Bupivacaine—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000237	0.00717	CbGpPWpGaD
Bupivacaine—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000232	0.00701	CbGpPWpGaD
Bupivacaine—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00023	0.00695	CbGpPWpGaD
Bupivacaine—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000227	0.00686	CbGpPWpGaD
Bupivacaine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00135	CcSEcCtD
Bupivacaine—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000222	0.00672	CbGpPWpGaD
Bupivacaine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.00134	CcSEcCtD
Bupivacaine—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000221	0.00667	CbGpPWpGaD
Bupivacaine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00133	CcSEcCtD
Bupivacaine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00133	CcSEcCtD
Bupivacaine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00133	CcSEcCtD
Bupivacaine—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000218	0.0066	CbGpPWpGaD
Bupivacaine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000218	0.00132	CcSEcCtD
Bupivacaine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000217	0.00131	CcSEcCtD
Bupivacaine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00131	CcSEcCtD
Bupivacaine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00131	CcSEcCtD
Bupivacaine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00131	CcSEcCtD
Bupivacaine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Bupivacaine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Bupivacaine—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000215	0.00649	CbGpPWpGaD
Bupivacaine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Bupivacaine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Bupivacaine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Bupivacaine—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000213	0.00643	CbGpPWpGaD
Bupivacaine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000213	0.00129	CcSEcCtD
Bupivacaine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00129	CcSEcCtD
Bupivacaine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000212	0.00128	CcSEcCtD
Bupivacaine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.00128	CcSEcCtD
Bupivacaine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000212	0.00128	CcSEcCtD
Bupivacaine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Bupivacaine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Bupivacaine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Bupivacaine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Bupivacaine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Bupivacaine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00127	CcSEcCtD
Bupivacaine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Bupivacaine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Bupivacaine—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Bupivacaine—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000209	0.00632	CbGpPWpGaD
Bupivacaine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00126	CcSEcCtD
Bupivacaine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000208	0.00125	CcSEcCtD
Bupivacaine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00125	CcSEcCtD
Bupivacaine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00125	CcSEcCtD
Bupivacaine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00125	CcSEcCtD
Bupivacaine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000206	0.00124	CcSEcCtD
Bupivacaine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00124	CcSEcCtD
Bupivacaine—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000204	0.00617	CbGpPWpGaD
Bupivacaine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00123	CcSEcCtD
Bupivacaine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00123	CcSEcCtD
Bupivacaine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00123	CcSEcCtD
Bupivacaine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00123	CcSEcCtD
Bupivacaine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00123	CcSEcCtD
Bupivacaine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00122	CcSEcCtD
Bupivacaine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00122	CcSEcCtD
Bupivacaine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Bupivacaine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Bupivacaine—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000199	0.00121	CcSEcCtD
Bupivacaine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00121	CcSEcCtD
Bupivacaine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Bupivacaine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Bupivacaine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Bupivacaine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Bupivacaine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Bupivacaine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Bupivacaine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Bupivacaine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000198	0.00119	CcSEcCtD
Bupivacaine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Bupivacaine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Bupivacaine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Bupivacaine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Bupivacaine—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000197	0.00594	CbGpPWpGaD
Bupivacaine—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000196	0.00591	CbGpPWpGaD
Bupivacaine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00118	CcSEcCtD
Bupivacaine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00118	CcSEcCtD
Bupivacaine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00117	CcSEcCtD
Bupivacaine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000193	0.00116	CcSEcCtD
Bupivacaine—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000192	0.00581	CbGpPWpGaD
Bupivacaine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00116	CcSEcCtD
Bupivacaine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00116	CcSEcCtD
Bupivacaine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00115	CcSEcCtD
Bupivacaine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Bupivacaine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Bupivacaine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Bupivacaine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Bupivacaine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.00114	CcSEcCtD
Bupivacaine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00114	CcSEcCtD
Bupivacaine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Bupivacaine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00113	CcSEcCtD
Bupivacaine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.00112	CcSEcCtD
Bupivacaine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00112	CcSEcCtD
Bupivacaine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00112	CcSEcCtD
Bupivacaine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00112	CcSEcCtD
Bupivacaine—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000185	0.00559	CbGpPWpGaD
Bupivacaine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00111	CcSEcCtD
Bupivacaine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00111	CcSEcCtD
Bupivacaine—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000183	0.00554	CbGpPWpGaD
Bupivacaine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000183	0.0011	CcSEcCtD
Bupivacaine—PTGER1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000182	0.0055	CbGpPWpGaD
Bupivacaine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000182	0.0011	CcSEcCtD
Bupivacaine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000181	0.0011	CcSEcCtD
Bupivacaine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Bupivacaine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Bupivacaine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Bupivacaine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Bupivacaine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.00018	0.00544	CbGpPWpGaD
Bupivacaine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00109	CcSEcCtD
Bupivacaine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Bupivacaine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Bupivacaine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Bupivacaine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Bupivacaine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000178	0.00108	CcSEcCtD
Bupivacaine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000178	0.00536	CbGpPWpGaD
Bupivacaine—Injury—Prednisone—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Bupivacaine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Bupivacaine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Bupivacaine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00106	CcSEcCtD
Bupivacaine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00106	CcSEcCtD
Bupivacaine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00106	CcSEcCtD
Bupivacaine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00106	CcSEcCtD
Bupivacaine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Bupivacaine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Bupivacaine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Bupivacaine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Bupivacaine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00105	CcSEcCtD
Bupivacaine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00104	CcSEcCtD
Bupivacaine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000172	0.00104	CcSEcCtD
Bupivacaine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Bupivacaine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Bupivacaine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00017	0.00515	CbGpPWpGaD
Bupivacaine—Pain—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00103	CcSEcCtD
Bupivacaine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00017	0.00103	CcSEcCtD
Bupivacaine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Bupivacaine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Bupivacaine—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Bupivacaine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000169	0.0051	CbGpPWpGaD
Bupivacaine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Bupivacaine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Bupivacaine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Bupivacaine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Bupivacaine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000166	0.00101	CcSEcCtD
Bupivacaine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Bupivacaine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Bupivacaine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Bupivacaine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Bupivacaine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000991	CcSEcCtD
Bupivacaine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000991	CcSEcCtD
Bupivacaine—PTGER1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000164	0.00495	CbGpPWpGaD
Bupivacaine—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000163	0.00493	CbGpPWpGaD
Bupivacaine—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000163	0.00492	CbGpPWpGaD
Bupivacaine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000163	0.000983	CcSEcCtD
Bupivacaine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000983	CcSEcCtD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000162	0.00489	CbGpPWpGaD
Bupivacaine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000162	0.00488	CbGpPWpGaD
Bupivacaine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000975	CcSEcCtD
Bupivacaine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000975	CcSEcCtD
Bupivacaine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Bupivacaine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Bupivacaine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Bupivacaine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Bupivacaine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00016	0.000967	CcSEcCtD
Bupivacaine—PTGER1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000159	0.00481	CbGpPWpGaD
Bupivacaine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000159	0.000958	CcSEcCtD
Bupivacaine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000955	CcSEcCtD
Bupivacaine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.000955	CcSEcCtD
Bupivacaine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000158	0.000953	CcSEcCtD
Bupivacaine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000158	0.000953	CcSEcCtD
Bupivacaine—PTGER1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000157	0.00476	CbGpPWpGaD
Bupivacaine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000951	CcSEcCtD
Bupivacaine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000951	CcSEcCtD
Bupivacaine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.000948	CcSEcCtD
Bupivacaine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000935	CcSEcCtD
Bupivacaine—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000153	0.00461	CbGpPWpGaD
Bupivacaine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000921	CcSEcCtD
Bupivacaine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000916	CcSEcCtD
Bupivacaine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000916	CcSEcCtD
Bupivacaine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.000905	CcSEcCtD
Bupivacaine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00015	0.000905	CcSEcCtD
Bupivacaine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00015	0.000904	CcSEcCtD
Bupivacaine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.00448	CbGpPWpGaD
Bupivacaine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000886	CcSEcCtD
Bupivacaine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000146	0.000881	CcSEcCtD
Bupivacaine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000146	0.000881	CcSEcCtD
Bupivacaine—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000144	0.00436	CbGpPWpGaD
Bupivacaine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000144	0.000869	CcSEcCtD
Bupivacaine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000144	0.000869	CcSEcCtD
Bupivacaine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000867	CcSEcCtD
Bupivacaine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000867	CcSEcCtD
Bupivacaine—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000143	0.00432	CbGpPWpGaD
Bupivacaine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000143	0.00431	CbGpPWpGaD
Bupivacaine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000143	0.000863	CcSEcCtD
Bupivacaine—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000142	0.0043	CbGpPWpGaD
Bupivacaine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000855	CcSEcCtD
Bupivacaine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000854	CcSEcCtD
Bupivacaine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00426	CbGpPWpGaD
Bupivacaine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000141	0.000851	CcSEcCtD
Bupivacaine—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000139	0.00421	CbGpPWpGaD
Bupivacaine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.00084	CcSEcCtD
Bupivacaine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000139	0.00084	CcSEcCtD
Bupivacaine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000836	CcSEcCtD
Bupivacaine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000832	CcSEcCtD
Bupivacaine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000828	CcSEcCtD
Bupivacaine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000136	0.000823	CcSEcCtD
Bupivacaine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000136	0.00082	CcSEcCtD
Bupivacaine—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000135	0.00407	CbGpPWpGaD
Bupivacaine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.000815	CcSEcCtD
Bupivacaine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.000812	CcSEcCtD
Bupivacaine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000134	0.000812	CcSEcCtD
Bupivacaine—PTGER1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000134	0.00405	CbGpPWpGaD
Bupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000134	0.00404	CbGpPWpGaD
Bupivacaine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000133	0.00401	CbGpPWpGaD
Bupivacaine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000795	CcSEcCtD
Bupivacaine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.000793	CcSEcCtD
Bupivacaine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00013	0.00392	CbGpPWpGaD
Bupivacaine—SCN4A—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	0.000129	0.00391	CbGpPWpGaD
Bupivacaine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000781	CcSEcCtD
Bupivacaine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000781	CcSEcCtD
Bupivacaine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.00387	CbGpPWpGaD
Bupivacaine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000127	0.000769	CcSEcCtD
Bupivacaine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000127	0.000769	CcSEcCtD
Bupivacaine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.000768	CcSEcCtD
Bupivacaine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000767	CcSEcCtD
Bupivacaine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000127	0.000765	CcSEcCtD
Bupivacaine—SCN10A—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	0.000125	0.00377	CbGpPWpGaD
Bupivacaine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000753	CcSEcCtD
Bupivacaine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.000744	CcSEcCtD
Bupivacaine—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000123	0.00372	CbGpPWpGaD
Bupivacaine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000743	CcSEcCtD
Bupivacaine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000737	CcSEcCtD
Bupivacaine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000731	CcSEcCtD
Bupivacaine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000121	0.000729	CcSEcCtD
Bupivacaine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000121	0.000729	CcSEcCtD
Bupivacaine—PTGER1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000121	0.00364	CbGpPWpGaD
Bupivacaine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.000726	CcSEcCtD
Bupivacaine—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.00358	CbGpPWpGaD
Bupivacaine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.000716	CcSEcCtD
Bupivacaine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000118	0.000714	CcSEcCtD
Bupivacaine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000706	CcSEcCtD
Bupivacaine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000703	CcSEcCtD
Bupivacaine—SCN4A—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000116	0.00349	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000115	0.00347	CbGpPWpGaD
Bupivacaine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000692	CcSEcCtD
Bupivacaine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000114	0.00346	CbGpPWpGaD
Bupivacaine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.000689	CcSEcCtD
Bupivacaine—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000112	0.0034	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000111	0.00337	CbGpPWpGaD
Bupivacaine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000665	CcSEcCtD
Bupivacaine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000665	CcSEcCtD
Bupivacaine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000654	CcSEcCtD
Bupivacaine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000649	CcSEcCtD
Bupivacaine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000643	CcSEcCtD
Bupivacaine—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000105	0.00319	CbGpPWpGaD
Bupivacaine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00318	CbGpPWpGaD
Bupivacaine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00317	CbGpPWpGaD
Bupivacaine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000631	CcSEcCtD
Bupivacaine—PTGER1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000104	0.00315	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000103	0.0031	CbGpPWpGaD
Bupivacaine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.0031	CbGpPWpGaD
Bupivacaine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000101	0.00306	CbGpPWpGaD
Bupivacaine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000608	CcSEcCtD
Bupivacaine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.95e-05	0.000601	CcSEcCtD
Bupivacaine—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.88e-05	0.00298	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	9.88e-05	0.00298	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	9.88e-05	0.00298	CbGpPWpGaD
Bupivacaine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.88e-05	0.000597	CcSEcCtD
Bupivacaine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	9.86e-05	0.000596	CcSEcCtD
Bupivacaine—Erythema—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.000592	CcSEcCtD
Bupivacaine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.000592	CcSEcCtD
Bupivacaine—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	9.74e-05	0.00294	CbGpPWpGaD
Bupivacaine—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	9.63e-05	0.00291	CbGpPWpGaD
Bupivacaine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.43e-05	0.00285	CbGpPWpGaD
Bupivacaine—Pain—Prednisolone—chronic obstructive pulmonary disease	9.41e-05	0.000569	CcSEcCtD
Bupivacaine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.31e-05	0.00281	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	9.25e-05	0.00279	CbGpPWpGaD
Bupivacaine—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	9.24e-05	0.00279	CbGpPWpGaD
Bupivacaine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	9.23e-05	0.000558	CcSEcCtD
Bupivacaine—PTGER1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	9.18e-05	0.00277	CbGpPWpGaD
Bupivacaine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.07e-05	0.000548	CcSEcCtD
Bupivacaine—Anaemia—Prednisone—chronic obstructive pulmonary disease	9.05e-05	0.000547	CcSEcCtD
Bupivacaine—Agitation—Prednisone—chronic obstructive pulmonary disease	9e-05	0.000544	CcSEcCtD
Bupivacaine—Angioedema—Prednisone—chronic obstructive pulmonary disease	8.95e-05	0.000541	CcSEcCtD
Bupivacaine—Syncope—Prednisone—chronic obstructive pulmonary disease	8.78e-05	0.000531	CcSEcCtD
Bupivacaine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.74e-05	0.000528	CcSEcCtD
Bupivacaine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.68e-05	0.00262	CbGpPWpGaD
Bupivacaine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.61e-05	0.00052	CcSEcCtD
Bupivacaine—Convulsion—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000513	CcSEcCtD
Bupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.49e-05	0.00256	CbGpPWpGaD
Bupivacaine—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.46e-05	0.000511	CcSEcCtD
Bupivacaine—PTGER1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	8.4e-05	0.00254	CbGpPWpGaD
Bupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.37e-05	0.00253	CbGpPWpGaD
Bupivacaine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.34e-05	0.000504	CcSEcCtD
Bupivacaine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.31e-05	0.00251	CbGpPWpGaD
Bupivacaine—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.000502	CcSEcCtD
Bupivacaine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000501	CcSEcCtD
Bupivacaine—PTGER1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	8.13e-05	0.00245	CbGpPWpGaD
Bupivacaine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.11e-05	0.00049	CcSEcCtD
Bupivacaine—PTGER1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	8.03e-05	0.00243	CbGpPWpGaD
Bupivacaine—Oedema—Prednisone—chronic obstructive pulmonary disease	7.99e-05	0.000483	CcSEcCtD
Bupivacaine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	7.99e-05	0.000483	CcSEcCtD
Bupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.99e-05	0.00241	CbGpPWpGaD
Bupivacaine—Infection—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.00048	CcSEcCtD
Bupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.88e-05	0.00238	CbGpPWpGaD
Bupivacaine—Shock—Prednisone—chronic obstructive pulmonary disease	7.87e-05	0.000475	CcSEcCtD
Bupivacaine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	7.84e-05	0.000474	CcSEcCtD
Bupivacaine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.000472	CcSEcCtD
Bupivacaine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.77e-05	0.000469	CcSEcCtD
Bupivacaine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000467	CcSEcCtD
Bupivacaine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.65e-05	0.00231	CbGpPWpGaD
Bupivacaine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.63e-05	0.0023	CbGpPWpGaD
Bupivacaine—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.31e-05	0.00221	CbGpPWpGaD
Bupivacaine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.28e-05	0.00044	CcSEcCtD
Bupivacaine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.28e-05	0.00044	CcSEcCtD
Bupivacaine—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000437	CcSEcCtD
Bupivacaine—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.23e-05	0.00218	CbGpPWpGaD
Bupivacaine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.18e-05	0.000434	CcSEcCtD
Bupivacaine—SCN4A—Developmental Biology—LEP—chronic obstructive pulmonary disease	7.18e-05	0.00217	CbGpPWpGaD
Bupivacaine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.04e-05	0.000425	CcSEcCtD
Bupivacaine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.95e-05	0.00042	CcSEcCtD
Bupivacaine—SCN10A—Developmental Biology—LEP—chronic obstructive pulmonary disease	6.92e-05	0.00209	CbGpPWpGaD
Bupivacaine—Headache—Prednisolone—chronic obstructive pulmonary disease	6.89e-05	0.000417	CcSEcCtD
Bupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.88e-05	0.00208	CbGpPWpGaD
Bupivacaine—Constipation—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000413	CcSEcCtD
Bupivacaine—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	6.75e-05	0.00204	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.73e-05	0.00203	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.65e-05	0.00201	CbGpPWpGaD
Bupivacaine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.59e-05	0.000398	CcSEcCtD
Bupivacaine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.54e-05	0.000395	CcSEcCtD
Bupivacaine—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.54e-05	0.000395	CcSEcCtD
Bupivacaine—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	6.51e-05	0.00197	CbGpPWpGaD
Bupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.48e-05	0.00196	CbGpPWpGaD
Bupivacaine—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	6.43e-05	0.00194	CbGpPWpGaD
Bupivacaine—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000384	CcSEcCtD
Bupivacaine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.32e-05	0.000382	CcSEcCtD
Bupivacaine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.32e-05	0.000382	CcSEcCtD
Bupivacaine—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	6.2e-05	0.00187	CbGpPWpGaD
Bupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.17e-05	0.00186	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	6.16e-05	0.00186	CbGpPWpGaD
Bupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.08e-05	0.00184	CbGpPWpGaD
Bupivacaine—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.08e-05	0.00184	CbGpPWpGaD
Bupivacaine—SCN4A—Axon guidance—MMP9—chronic obstructive pulmonary disease	6.05e-05	0.00183	CbGpPWpGaD
Bupivacaine—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.99e-05	0.00181	CbGpPWpGaD
Bupivacaine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.000356	CcSEcCtD
Bupivacaine—SCN10A—Axon guidance—MMP9—chronic obstructive pulmonary disease	5.83e-05	0.00176	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	5.8e-05	0.00175	CbGpPWpGaD
Bupivacaine—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.74e-05	0.000347	CcSEcCtD
Bupivacaine—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.7e-05	0.00172	CbGpPWpGaD
Bupivacaine—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.66e-05	0.000342	CcSEcCtD
Bupivacaine—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.63e-05	0.0017	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.59e-05	0.00169	CbGpPWpGaD
Bupivacaine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.51e-05	0.00166	CbGpPWpGaD
Bupivacaine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.47e-05	0.000331	CcSEcCtD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	5.47e-05	0.00165	CbGpPWpGaD
Bupivacaine—SCN4A—Axon guidance—VEGFA—chronic obstructive pulmonary disease	5.43e-05	0.00164	CbGpPWpGaD
Bupivacaine—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000319	CcSEcCtD
Bupivacaine—PTGER1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	5.27e-05	0.00159	CbGpPWpGaD
Bupivacaine—SCN10A—Axon guidance—VEGFA—chronic obstructive pulmonary disease	5.24e-05	0.00158	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	5.19e-05	0.00157	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.14e-05	0.00155	CbGpPWpGaD
Bupivacaine—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.08e-05	0.000307	CcSEcCtD
Bupivacaine—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.07e-05	0.00153	CbGpPWpGaD
Bupivacaine—Headache—Prednisone—chronic obstructive pulmonary disease	5.01e-05	0.000303	CcSEcCtD
Bupivacaine—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5e-05	0.00151	CbGpPWpGaD
Bupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5e-05	0.00151	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.96e-05	0.0015	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.96e-05	0.0015	CbGpPWpGaD
Bupivacaine—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	4.94e-05	0.00149	CbGpPWpGaD
Bupivacaine—SCN4A—Axon guidance—EGFR—chronic obstructive pulmonary disease	4.89e-05	0.00148	CbGpPWpGaD
Bupivacaine—Nausea—Prednisone—chronic obstructive pulmonary disease	4.75e-05	0.000287	CcSEcCtD
Bupivacaine—SCN10A—Axon guidance—EGFR—chronic obstructive pulmonary disease	4.71e-05	0.00142	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.71e-05	0.00142	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.66e-05	0.00141	CbGpPWpGaD
Bupivacaine—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.66e-05	0.00141	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.63e-05	0.0014	CbGpPWpGaD
Bupivacaine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.6e-05	0.00139	CbGpPWpGaD
Bupivacaine—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.59e-05	0.00139	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.54e-05	0.00137	CbGpPWpGaD
Bupivacaine—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.42e-05	0.00133	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.4e-05	0.00133	CbGpPWpGaD
Bupivacaine—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.35e-05	0.00132	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.35e-05	0.00131	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—MMP9—chronic obstructive pulmonary disease	4.31e-05	0.0013	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.28e-05	0.00129	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.25e-05	0.00128	CbGpPWpGaD
Bupivacaine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.22e-05	0.00128	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.17e-05	0.00126	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.17e-05	0.00126	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—MMP9—chronic obstructive pulmonary disease	4.16e-05	0.00126	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	4.12e-05	0.00124	CbGpPWpGaD
Bupivacaine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.06e-05	0.00123	CbGpPWpGaD
Bupivacaine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.01e-05	0.00121	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4e-05	0.00121	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.97e-05	0.0012	CbGpPWpGaD
Bupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.97e-05	0.0012	CbGpPWpGaD
Bupivacaine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.95e-05	0.00119	CbGpPWpGaD
Bupivacaine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.89e-05	0.00118	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	3.87e-05	0.00117	CbGpPWpGaD
Bupivacaine—SCN4A—Axon guidance—IL6—chronic obstructive pulmonary disease	3.76e-05	0.00113	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	3.74e-05	0.00113	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.65e-05	0.0011	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.63e-05	0.0011	CbGpPWpGaD
Bupivacaine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.63e-05	0.0011	CbGpPWpGaD
Bupivacaine—SCN10A—Axon guidance—IL6—chronic obstructive pulmonary disease	3.62e-05	0.00109	CbGpPWpGaD
Bupivacaine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.6e-05	0.00109	CbGpPWpGaD
Bupivacaine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.58e-05	0.00108	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	3.56e-05	0.00107	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.55e-05	0.00107	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—EGFR—chronic obstructive pulmonary disease	3.49e-05	0.00105	CbGpPWpGaD
Bupivacaine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.44e-05	0.00104	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	3.43e-05	0.00104	CbGpPWpGaD
Bupivacaine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.39e-05	0.00102	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.37e-05	0.00102	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—EGFR—chronic obstructive pulmonary disease	3.36e-05	0.00102	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—TNF—chronic obstructive pulmonary disease	3.32e-05	0.001	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.27e-05	0.000987	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—TNF—chronic obstructive pulmonary disease	3.2e-05	0.000967	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.11e-05	0.000941	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.05e-05	0.000921	CbGpPWpGaD
Bupivacaine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.01e-05	0.000908	CbGpPWpGaD
Bupivacaine—PTGER1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.8e-05	0.000847	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.8e-05	0.000846	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.78e-05	0.000841	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.77e-05	0.000836	CbGpPWpGaD
Bupivacaine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.76e-05	0.000834	CbGpPWpGaD
Bupivacaine—SCN4A—Developmental Biology—IL6—chronic obstructive pulmonary disease	2.68e-05	0.000809	CbGpPWpGaD
Bupivacaine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.66e-05	0.000802	CbGpPWpGaD
Bupivacaine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.62e-05	0.000791	CbGpPWpGaD
Bupivacaine—SCN10A—Developmental Biology—IL6—chronic obstructive pulmonary disease	2.58e-05	0.00078	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.55e-05	0.000769	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.53e-05	0.000765	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.53e-05	0.000764	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.43e-05	0.000735	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.35e-05	0.000711	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.33e-05	0.000705	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.29e-05	0.000691	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.26e-05	0.000684	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.16e-05	0.000654	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.14e-05	0.000645	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.13e-05	0.000643	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.11e-05	0.000636	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.97e-05	0.000596	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.96e-05	0.000591	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.86e-05	0.000562	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.83e-05	0.000554	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.78e-05	0.000539	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.78e-05	0.000536	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.7e-05	0.000512	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.7e-05	0.000512	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.66e-05	0.000501	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.5e-05	0.000454	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.43e-05	0.000432	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.41e-05	0.000427	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.38e-05	0.000416	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.36e-05	0.000411	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.32e-05	0.000399	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.28e-05	0.000387	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.25e-05	0.000378	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.24e-05	0.000373	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.22e-05	0.000369	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.15e-05	0.000348	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.15e-05	0.000347	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.14e-05	0.000343	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.13e-05	0.000341	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.12e-05	0.000339	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.1e-05	0.000332	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.04e-05	0.000314	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.04e-05	0.000313	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.74e-06	0.000294	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.63e-06	0.000291	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.56e-06	0.000289	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	9.23e-06	0.000279	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.98e-06	0.000271	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.79e-06	0.000265	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.67e-06	0.000262	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.55e-06	0.000258	CbGpPWpGaD
Bupivacaine—PTGER1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	8.45e-06	0.000255	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.97e-06	0.000241	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.96e-06	0.000241	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.86e-06	0.000237	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.55e-06	0.000228	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.52e-06	0.000227	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.43e-06	0.000225	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.33e-06	0.000221	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.94e-06	0.00021	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.78e-06	0.000205	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.75e-06	0.000204	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.66e-06	0.000201	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.25e-06	0.000189	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.21e-06	0.000187	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.88e-06	0.000178	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.21e-06	0.000157	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.14e-06	0.000155	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.13e-06	0.000155	CbGpPWpGaD
Bupivacaine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	4.91e-06	0.000148	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.79e-06	0.000145	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.72e-06	0.000143	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.54e-06	0.000137	CbGpPWpGaD
Bupivacaine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.52e-06	0.000136	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4e-06	0.000121	CbGpPWpGaD
Bupivacaine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.83e-06	0.000116	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.09e-06	9.32e-05	CbGpPWpGaD
Bupivacaine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.95e-06	8.92e-05	CbGpPWpGaD
